Effects of GABA Modulator AZD7325 on Cutaneous Sensation

Inclusion criteria

• Male adults aged 18 to 55 years (extremes are included)
• A body weight resulting in a body mass index (BMI) of 18-30 kg/m2 (extremes included) using the formula BMI = body-weight [in kg] / body-height [in m]2
• Able and willing to sign the Informed Consent Form prior to screening evaluations.
• History of good physical and mental health as determined by history taking and laboratory examinations, ECG, blood pressure and heart rate recordings as judged by the investigator
• Willing not to consume alcohol or to smoke or chew tobacco on days of assessments
• Subjects must be willing to avoid unprotected vaginal intercourse with women of child bearing potential (see above under 3.5) or donating sperm for the duration of the study and a further 1 week after drug administration.

Exclusion criteria

• History of allergy/idiosyncrasy to AZD7325 or chemically related compounds or excipients which may be employed in the study or to any other drug used in the past
• Subject has taken systemically (po, iv) any potent or moderate CYP3A4 or CYP2C9 inhibitor, 1 month prior to screening (topical or inhaled are permitted) such as: aprepitant, barbiturates, carbamazepine, clarithromycin, erythromycin, cyclosporine, diltiazem, efavirenz, fluconazole, HIV protease inhibitors, glucocorticoids, itraconazole (oral/IV), ketoconazole, nefazodone, nevirapine, phenytoin, pioglitazone, primidone, rifabutin, rifampicin, telithromycin, St. John's wort, verapamil
• Use of any prescription drug judged by the investigator as potentially interfering with this trial within two weeks prior to the first dosing, except for topical medication without systemic exposure
• Clinically relevant history or presence of any medical disorder, potentially interfering with this trial
• Clinically relevant abnormal laboratory, ECG, HR or BP at screening as judged by the investigator
• History of or current abuse of drugs (including prescription medication) or alcohol or solvents
• Smoking in excess of 5 cigarettes per day or the equivalent within 28 days prior to the screening visit
• Smoking or chewing of tobacco or consume of alcohol, 24 hours before and on the days of assessment
• Subject is family member or in the employment line management of study personnel
• Subject has abnormal screening laboratory values
• Subject's partner is planning pregnancy within 3 months of last dosing
• Participation in an IMP intervention trial within last month or more than four in the previous 12 months
• Abnormal responses in the object manipulation task and psychophysical measures, SDMT, VAS outside 95% confidence interval of normal at screening visit
• Subjects with a history of epilepsy, seizures or episodes of unexplained and unprovoked loss of consciousness